{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:19:05Z","timestamp":1788484745971,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ashjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Hypertension"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jash.2015.11.005","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T06:01:08Z","timestamp":1448949668000},"page":"55-69.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension"],"prefix":"10.1016","volume":"10","author":[{"given":"Leo","family":"Akioyamen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sherifali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-3333","authenticated-orcid":false,"given":"Claudia","family":"Frankfurter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Pullenayegum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Goeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.jash.2015.11.005_bib1","first-page":"S3","article-title":"Discovery of losartan, the first angiotensin II receptor antagonist","volume":"9","author":"Timmermans","year":"1995","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","article-title":"Angiotensin II type 1 receptor blockers","volume":"103","author":"Burnier","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2015.11.005_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3122\/jabfm.2007.01.060094","article-title":"Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies","volume":"20","author":"Elliott","year":"2007","journal-title":"J Am Board Fam Med JABFM"},{"key":"10.1016\/j.jash.2015.11.005_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200626040-00002","article-title":"Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals","volume":"26","author":"Brunner","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jash.2015.11.005_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/00004872-200404000-00028","article-title":"Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension","volume":"22","author":"Calvo","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","article-title":"Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension","volume":"9","author":"Giles","year":"2007","journal-title":"J Clin Hypertens Greenwich Conn"},{"key":"10.1016\/j.jash.2015.11.005_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1742-1241.2004.00409.x","article-title":"A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients","author":"Lee","year":"2004","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.jash.2015.11.005_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200868090-00003","article-title":"Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension","volume":"68","author":"Smith","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jash.2015.11.005_bib9","first-page":"253","article-title":"Angiotensin II antagonists in the treatment of hypertension: more similarities than differences","volume":"2","author":"Conlin","year":"2000","journal-title":"J Clin Hypertens Greenwich Conn"},{"key":"10.1016\/j.jash.2015.11.005_bib10","first-page":"1393","article-title":"2011 Canadian Hypertension Education Program recommendations: an annual update","volume":"57","author":"Canadian Hypertension Education Program","year":"2011","journal-title":"Can Fam Physician M\u00e9decin Fam Can"},{"key":"10.1016\/j.jash.2015.11.005_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jash.2015.11.005_bib12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2015.11.005_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jash.2015.11.005_bib14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jash.2015.11.005_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2015.11.005_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.CIR.101.3.329","article-title":"Essential hypertension. Part I: definition and etiology","volume":"101","author":"Carretero","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2015.11.005_bib17","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jash.2015.11.005_bib18","unstructured":"Tsoi B, Pullenayegum E, Levine M, Frankfurter C, Akioyamen L, Goeree R: Comparative effectiveness of angiotensin receptor blockers for the primary prevention of cardiovascular and cerebrovascular outcomes: a meta-analysis. PROSPERO: CRD42014007067\u00a02014."},{"key":"10.1016\/j.jash.2015.11.005_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.HYP.38.2.183","article-title":"Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP","volume":"38","author":"Siragy","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.jash.2015.11.005_bib20","doi-asserted-by":"crossref","unstructured":"Higgins J. and Altman D.G. (2008) Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0 (eds J. Higgins & S. Green). Available at: http:\/\/www.cochrane-handbook.org (last accessed 20 July 2010).","DOI":"10.1002\/9780470712184.ch8"},{"key":"10.1016\/j.jash.2015.11.005_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2015.11.005_bib22","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1097\/01.hjh.0000220415.99610.22","article-title":"The Study on COgnition and Prognosis in the Elderly (SCOPE)\u2013recent analyses","volume":"24","author":"Trenkwalder","year":"2006","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.jash.2015.11.005_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jash.2015.11.005_bib25","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"19 Pt 2","key":"10.1016\/j.jash.2015.11.005_bib26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/01.wnl.0000311447.85948.78","article-title":"Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial","volume":"70","author":"Saxby","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jash.2015.11.005_bib27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2015.11.005_bib28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1291\/hypres.27.457","article-title":"Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study","volume":"27","author":"DeRosa","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2015.11.005_bib29","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000000154","article-title":"Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis","volume":"32","author":"Foulquier","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jash.2015.11.005_bib31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/HJH.0b013e328351856d","article-title":"Prevention of microalbuminuria in patients with type 2 diabetes and hypertension","volume":"30","author":"Menne","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib32","first-page":"1175","article-title":"Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"44","author":"Papademetriou","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2015.11.005_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabres.2007.08.004","article-title":"A renoprotective effect of low dose losartan in patients with type 2 diabetes","volume":"79","author":"Sawaki","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jash.2015.11.005_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08037050510008823","article-title":"The Study on COgnition and Prognosis in the Elderly (SCOPE)\u2014major CV events and stroke in subgroups of patients","volume":"14","author":"Trenkwalder","year":"2005","journal-title":"Blood Press"},{"key":"10.1016\/j.jash.2015.11.005_bib35","doi-asserted-by":"crossref","first-page":"941783","DOI":"10.1155\/2013\/941783","article-title":"Elevated blood pressure in the acute phase of stroke and the role of angiotensin receptor blockers","volume":"2013","author":"Lattanzi","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","article-title":"Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension","volume":"20","author":"Cheung","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/HJH.0b013e32832961ed","article-title":"Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials","volume":"27","author":"Volpe","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib38","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials","volume":"342","author":"Bangalore","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2015.11.005_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1472-8206.2005.00356.x","article-title":"Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments","volume":"19","author":"Boissel","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jash.2015.11.005_bib40","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1161\/STROKEAHA.109.559989","article-title":"A systematic review of angiotensin receptor blockers in preventing stroke","volume":"40","author":"Lu","year":"2009","journal-title":"Stroke J Cereb Circ"},{"key":"10.1016\/j.jash.2015.11.005_bib41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCULATIONAHA.105.594978","article-title":"Angiotensin receptor blockers do not increase risk of myocardial infarction","volume":"114","author":"Tsuyuki","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2015.11.005_bib42","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/HJH.0000000000000183","article-title":"Are the effects of telmisartan more marked in hypertensive patients?","volume":"32","author":"Chalmers","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jash.2015.11.005_bib44","first-page":"1","article-title":"Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy","volume":"7","author":"Law","year":"2003","journal-title":"Health Technol Assess Winch Engl"},{"key":"10.1016\/j.jash.2015.11.005_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0828-282X(07)70803-6","article-title":"More medications, fewer pills: combination medications for the treatment of hypertension","volume":"23","author":"Lewanczuk","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jash.2015.11.005_bib46","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jash.2015.11.005_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MJT.0b013e31804beb59","article-title":"Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis","volume":"15","author":"Jibrini","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.jash.2015.11.005_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11906-004-0019-3","article-title":"Are angiotensin receptor blockers neuroprotective?","volume":"6","author":"Th\u00f6ne-Reineke","year":"2004","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jash.2015.11.005_bib49","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1161\/STROKEAHA.109.559062","article-title":"Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings no","volume":"40","author":"Strauss","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jash.2015.11.005_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1037\/1082-989X.8.3.243","article-title":"How meta-analysis increases\u00a0statistical power","volume":"8","author":"Cohn","year":"2003","journal-title":"Psychol Methods"},{"key":"10.1016\/j.jash.2015.11.005_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1037\/1082-989X.13.1.31","article-title":"Confidence intervals for the overall effect size in random-effects meta-analysis","volume":"13","author":"S\u00e1nchez-Meca","year":"2008","journal-title":"Psychol Methods"},{"key":"10.1016\/j.jash.2015.11.005_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256593","article-title":"Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis","volume":"9","author":"Al Khalaf","year":"2009","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"10.1016\/j.jash.2015.11.005_bib53","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/01.hjh.0000354516.44580.ca","article-title":"Main results and clinical interpretations from the TRANSCEND study","volume":"27","author":"De la Sierra","year":"2009","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.jash.2015.11.005_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1291\/hypres.27.755","article-title":"Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study","volume":"27","author":"Ohkubo","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jash.2015.11.005_bib55","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jash.2015.11.005_bib56","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1097\/HJH.0b013e328364ca4c","volume":"31","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.jash.2015.11.005_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system","volume":"109","author":"L\u00e9vy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jash.2015.11.005_bib58","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.peptides.2005.03.010","article-title":"The AT2 receptor\u2013a matter of love and hate","volume":"26","author":"Steckelings","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.jash.2015.11.005_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jash.2015.11.005_bib60","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jclinepi.2006.06.018","article-title":"Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation","volume":"60","author":"Thiessen Philbrook","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jash.2015.11.005_bib61","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1359-6446(04)03274-X","article-title":"Beyond classical meta-analysis: can inadequately reported studies be included?","volume":"9","author":"Robertson","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jash.2015.11.005_bib62","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1093\/eurheartj\/ehu364","article-title":"Non-adherence to cardiovascular medications","volume":"35","author":"Kolandaivelu","year":"2014","journal-title":"Eur Heart J"}],"container-title":["Journal of the American Society of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171115007871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933171115007871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T04:26:05Z","timestamp":1537158365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933171115007871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1933171115007871"],"URL":"https:\/\/doi.org\/10.1016\/j.jash.2015.11.005","relation":{},"ISSN":["1933-1711"],"issn-type":[{"value":"1933-1711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jash.2015.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}